Multiple sclerosis does not prevent a healthy pregnancy, and for many women, pregnancy is actually one of the calmest periods of disease activity they experience. Relapse rates drop significantly as pregnancy progresses, particularly in the third trimester, where they can fall by as much as 70% compared to the year before conception. The real challenge comes after delivery, when relapse risk roughly doubles in the first three months postpartum. Understanding this pattern, along with what it means for your baby, your medications, and your long-term health, can help you plan with confidence.
Fertility and MS
MS itself does not appear to directly reduce fertility. A large population-based study found that women with MS have fewer children on average (1.5 live births versus 1.8 in the general population), but the researchers noted this difference likely reflects personal decisions, prodromal symptoms, and the timing of diagnosis rather than a biological inability to conceive. Interestingly, birth rates among women with MS start dipping about three years before symptom onset, with only 4.5% giving birth two years before onset compared to 8.4% of matched controls. This suggests that the early, often unrecognized phase of MS may influence family planning through fatigue, subtle symptoms, or other factors before anyone knows MS is the cause.
Women with MS also tend to have their first child slightly later, around age 27 compared to 26 in the general population. The gap is small, and there’s no evidence that MS damages the reproductive system. If you’re having trouble conceiving, the usual fertility considerations apply just as they would for anyone else.
How Pregnancy Changes Relapse Risk
Pregnancy creates a natural shift in the immune system. To protect the developing baby, the body dials down certain immune responses, and since MS is driven by an overactive immune system attacking the nervous system, this suppression works in your favor. Relapse rates decline steadily across all three trimesters. In the landmark PRIMS study of 225 women, only 12 (about 5%) experienced a relapse during the third trimester, translating to an annualized rate of just 0.2 relapses per year.
This protective effect is temporary. Within the first three months after delivery, relapse rates nearly double compared to pre-pregnancy levels. A meta-analysis published in the Journal of Neurology, Neurosurgery & Psychiatry found the incidence rate ratio was 1.87 in the first three months postpartum, with elevated risk persisting through the first six months. After that window, most women return to their baseline relapse pattern.
What This Means for Your Baby
Babies born to mothers with MS are generally healthy. The risk of congenital anomalies (birth defects) is not meaningfully increased. The largest cohort study on this question, using Danish registry data covering nearly two decades of births, found no significant difference in the rate of birth defects between MS and non-MS pregnancies.
There is a modest increase in the chance of preterm birth. Several large studies have estimated the risk is about 15% to 30% higher than in the general population, though the absolute numbers remain relatively low. Some studies also show a slightly higher chance of babies being born smaller for their gestational age, with odds ratios ranging from 1.29 to 1.89 depending on the study population. These are statistical tendencies, not certainties, and most pregnancies in women with MS result in full-term, healthy babies.
Will Your Child Develop MS?
MS is not inherited in a straightforward way, but genetics do play a role. The overall risk for a child of a parent with MS is roughly 1% to 2%, compared to about 0.1% to 0.3% in the general population. Swedish registry data puts the sibling recurrence risk at 2.6% and the risk for identical twins at 17.3%, which underscores that genes matter but are far from the whole story. Environmental factors, including where a child grows up, vitamin D exposure, and infections during childhood, also shape the risk. Having MS does not mean your child will develop it.
Managing Medications Before and During Pregnancy
This is the area that requires the most planning. Some MS medications are safe to continue into early pregnancy, while others must be stopped well in advance.
- Considered safe in early pregnancy: Interferon-beta formulations, glatiramer acetate, and fumarates have shown reassuring safety profiles in registry studies and are options for women with mild to moderate disease activity.
- Contraindicated or should be avoided: Teriflunomide, cladribine, and S1P receptor modulators (such as fingolimod) are contraindicated due to potential risks to the developing baby. Alemtuzumab should also be avoided during pregnancy. These medications require washout periods before conception, and the timeline varies by drug.
The specific washout period depends on which medication you’re taking and how long it stays active in your body. Your neurologist will help you develop a timeline. For many women, the ideal approach is to plan the pregnancy in advance so there’s time to transition off a contraindicated medication and, if needed, bridge to a safer option. Stopping treatment abruptly without a plan can trigger rebound disease activity, so this is not a decision to make on your own.
Labor, Delivery, and Anesthesia
MS does not dictate how you deliver your baby. Vaginal delivery and cesarean section are both options, and the choice depends on obstetric factors, not MS itself. One common concern is whether epidurals and spinal anesthesia are safe. A systematic review covering over 1,100 MS patients who received neuraxial anesthesia (epidurals or spinal blocks) found that severe complications were rare. Some case reports documented temporary issues like heightened sensitivity or brief neurological symptoms, but postpartum relapses observed in these studies were not linked to the anesthetic technique itself. Most patients experienced no significant lasting effects.
Fatigue and weakness during labor can be more pronounced for women with MS, especially those who already experience these symptoms day to day. Discussing a birth plan with both your neurologist and obstetrician helps ensure your care team is prepared.
Breastfeeding and Postpartum Protection
Breastfeeding appears to offer a real protective benefit against postpartum relapses. A meta-analysis of 24 studies covering nearly 3,000 women found that breastfeeding was associated with a 43% lower rate of postpartum relapse compared to not breastfeeding. Exclusive breastfeeding for at least two months showed an even stronger effect, cutting the odds of relapse nearly in half.
The likely explanation ties back to hormones. Exclusive breastfeeding suppresses the return of the menstrual cycle and maintains some of the immune shifts that protected you during pregnancy. The benefit appears greatest in women who breastfeed exclusively (no formula supplementation) for at least the first two months. That said, some women need to restart MS medications quickly after delivery, and certain drugs are not compatible with breastfeeding. This is a conversation that should happen before delivery so you have a clear plan.
Long-Term Effects of Pregnancy on MS
One of the most reassuring findings in MS research is that pregnancy does not worsen the long-term course of the disease. A nationwide Danish cohort study compared 425 women who became mothers after their MS diagnosis with 840 who did not. Pregnancy showed no association with reaching major disability milestones. The hazard ratios for progressing to moderate disability (EDSS 4) and needing a walking aid (EDSS 6) were both below 1.0, meaning mothers with MS fared at least as well as, and possibly slightly better than, women who did not have children.
The postpartum relapse spike, while real, is temporary and does not appear to leave a lasting mark on disability over the years. Some researchers have even speculated that the immune recalibration of pregnancy may have subtle long-term benefits, though this remains unproven. What the data clearly show is that having a baby does not accelerate MS progression.